Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06840899 · ClinicalTrials.gov registry record · Phase 2
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
A Phase 2 study of Spinal Cord Injury and Urinary Incontinence, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06840899: Recruiting Phase 2 study of Spinal Cord Injury and Urinary Incontinence, sponsored by University of Wisconsin, Madison.
NCT06840899 is a Phase 2 study of Spinal Cord Injury and Urinary Incontinence that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 20 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06840899, a Phase 2 study of Spinal Cord Injury and Urinary Incontinence, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI). Participants will take Epidiolex (purified CBD) for 90 days
Primary Outcome
Participants will complete a daily smartphone application-based drug diary recording when they take study drug.
Conditions Studied
Interventions
- DRUG CBD
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What NCT06840899 shows while recruiting
NCT06840899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Spinal Cord Injury appearing as the primary indexed condition, and to 1 intervention - of which CBD is the first listed.
NCT06840899 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06840899 about?
NCT06840899 is a clinical study titled "CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury". The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI). Participants will take Epidiolex (purified CBD) for 90 days
What is the current status of trial NCT06840899?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-02-13. Estimated completion is 2027-05.
What conditions does trial NCT06840899 study?
This clinical trial studies the following conditions: Spinal Cord Injury, Urinary Incontinence, Supra-sacral Spinal Cord Injury.
What interventions are being tested in trial NCT06840899?
The interventions under investigation include: CBD (DRUG).
Who is sponsoring clinical trial NCT06840899?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06840899 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06840899's enrollment target sits among peer trials
20 55th of 99 higher than 41 of 99 other Spinal Cord Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Cord Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury
RECRUITING · Phase 2
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
-
Electrical Control of Bladder in Spinal Cord Injury Patients
COMPLETED · Phase 2
-
Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury.
COMPLETED · Phase 2
-
Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial
COMPLETED · Phase 2
-
Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI